158 related articles for article (PubMed ID: 15653410)
1. Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy.
Hofmann WP; Zeuzem S; Sarrazin C
J Clin Virol; 2005 Feb; 32(2):86-91. PubMed ID: 15653410
[TBL] [Abstract][Full Text] [Related]
2. [Hepatitis C-virus --virus kinetics and resistance mechanisms].
Herrmann E; Sarrazin C
Z Gastroenterol; 2004 May; 42(5):387-96. PubMed ID: 15136939
[TBL] [Abstract][Full Text] [Related]
3. NS5A(ISDR-V3) region genetic variability of Tunisian HCV-1b strains: Correlation with the response to the combined interferon/ribavirin therapy.
Bouzgarrou N; Hassen E; Mahfoudh W; Gabbouj S; Schvoerer E; Ben Yahia A; Ben Mami N; Triki H; Chouchane L
J Med Virol; 2009 Dec; 81(12):2021-8. PubMed ID: 19856481
[TBL] [Abstract][Full Text] [Related]
4. Mutations within the CD81-binding sites and hypervariable region 2 of the envelope 2 protein: correlation with treatment response in hepatitis C virus-infected patients.
Hofmann WP; Sarrazin C; Kronenberger B; Schönberger B; Bruch K; Zeuzem S
J Infect Dis; 2003 Mar; 187(6):982-7. PubMed ID: 12660945
[TBL] [Abstract][Full Text] [Related]
5. Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b.
Saito T; Ito T; Ishiko H; Yonaha M; Morikawa K; Miyokawa A; Mitamura K
Am J Gastroenterol; 2003 Jun; 98(6):1377-83. PubMed ID: 12818284
[TBL] [Abstract][Full Text] [Related]
6. Mutations in NS5A region of hepatitis C virus genome correlate with presence of NS5A antibodies and response to interferon therapy for most common European hepatitis C virus genotypes.
Frangeul L; Cresta P; Perrin M; Lunel F; Opolon P; Agut H; Huraux JM
Hepatology; 1998 Dec; 28(6):1674-9. PubMed ID: 9828234
[TBL] [Abstract][Full Text] [Related]
7. [Association between NS5A gene sequence and response to interferon therapy in chronic hepatitis C patients in Shanghai].
Hu Y; Tang M; Jiang W; Wu Y; Yuan Z; Wen Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Jun; 16(2):114-8. PubMed ID: 12196819
[TBL] [Abstract][Full Text] [Related]
8. A mutation in the interferon sensitivity-determining region is associated with responsiveness to interferon-ribavirin combination therapy in chronic hepatitis patients infected with a Japan-specific subtype of hepatitis C virus genotype 1B.
Murayama M; Katano Y; Nakano I; Ishigami M; Hayashi K; Honda T; Hirooka Y; Itoh A; Goto H
J Med Virol; 2007 Jan; 79(1):35-40. PubMed ID: 17133546
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C virus and the controversial role of the interferon sensitivity determining region in the response to interferon treatment.
Torres-Puente M; Cuevas JM; Jiménez-Hernández N; Bracho MA; García-Robles I; Carnicer F; del Olmo J; Ortega E; Moya A; González-Candelas F
J Med Virol; 2008 Feb; 80(2):247-53. PubMed ID: 18098147
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
[TBL] [Abstract][Full Text] [Related]
11. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
[TBL] [Abstract][Full Text] [Related]
12. Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment.
Mancini N; Carletti S; Perotti M; Romanò L; Craxì RD; Craxì A; Zanetti AR; Clementi M; Burioni R
J Med Virol; 2006 Oct; 78(10):1304-11. PubMed ID: 16927283
[TBL] [Abstract][Full Text] [Related]
13. Mutations in the NS5A gene are associated with response to interferon+ribavirin combination therapy in patients with chronic hepatitis C virus 3a infection.
Ullah S; Rehman HU; Idrees M
Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1146-51. PubMed ID: 23611896
[TBL] [Abstract][Full Text] [Related]
14. Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
Raziorrouh B; Jung MC; Schirren CA; Loehe F; Thiel M; Nitschko H; Diepolder H; Ulsenheimer A; Heeg M; Zachoval R; Gruener NH
Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):778-83. PubMed ID: 18617783
[TBL] [Abstract][Full Text] [Related]
15. The molecular basis for responsiveness to anti-viral therapy in hepatitis C.
Polyak SJ; Gerotto M
Forum (Genova); 2000; 10(1):46-58. PubMed ID: 10717257
[TBL] [Abstract][Full Text] [Related]
16. Interferon sensitivity-determining region of nonstructural region 5A of hepatitis C virus genotype 1b correlates with serum alanine aminotransferase levels in chronic infection.
Yoshioka K; Ito H; Watanabe K; Yano M; Ishigami M; Mizutani T; Sasaki Y; Goto H
J Viral Hepat; 2005 Mar; 12(2):139-45. PubMed ID: 15720528
[TBL] [Abstract][Full Text] [Related]
17. Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin.
Hung CH; Lee CM; Lu SN; Lee JF; Wang JH; Tung HD; Chen TM; Hu TH; Chen WJ; Changchien CS
J Viral Hepat; 2003 Mar; 10(2):87-94. PubMed ID: 12614464
[TBL] [Abstract][Full Text] [Related]
18. Amino acid substitutions in the nonstructural region 5A of hepatitis C virus genotypes 2a and 2b and its relation to viral load and response to interferon.
Kobayashi M; Watanabe K; Ishigami M; Murase K; Ito H; Ukai K; Yano M; Takagi K; Hattori M; Kakumu S; Yoshioka K
Am J Gastroenterol; 2002 Apr; 97(4):988-98. PubMed ID: 12003437
[TBL] [Abstract][Full Text] [Related]
19. Analysis of sequence configurations of the PKR-interacting HCV proteins from plasma and PBMC as predictors of response to interferon-alpha and ribavirin therapy in HIV-coinfected patients.
Bolcic F; Bull L; Martinez L; Reynoso R; Salomon H; Arduino R; Barnett B; Quarleri J
Intervirology; 2008; 51(4):261-4. PubMed ID: 18824873
[No Abstract] [Full Text] [Related]
20. Mutations in the putative HCV-E2 CD81 binding regions and correlation with cell surface CD81 expression.
Kronenberger B; Sarrazin C; Hofmann WP; von Wagner M; Herrmann E; Welsch C; Elez R; Rüster B; Piiper A; Zeuzem S
J Viral Hepat; 2004 Jul; 11(4):310-8. PubMed ID: 15230853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
